Collegium Pharmaceutical Inc (COLL)vsUnited Therapeutics Corporation (UTHR)
COLL
Collegium Pharmaceutical Inc
$37.80
-3.89%
HEALTHCARE · Cap: $1.11B
UTHR
United Therapeutics Corporation
$564.94
-0.74%
HEALTHCARE · Cap: $24.16B
Smart Verdict
WallStSmart Research — data-driven comparison
United Therapeutics Corporation generates 306% more annual revenue ($3.17B vs $780.57M). UTHR leads profitability with a 40.6% profit margin vs 8.1%. COLL trades at a lower P/E of 19.8x. COLL earns a higher WallStSmart Score of 65/100 (B-).
COLL
Strong Buy65
out of 100
Grade: B-
UTHR
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+89.2%
Fair Value
$416.48
Current Price
$37.80
$378.68 discount
Margin of Safety
+11.2%
Fair Value
$535.96
Current Price
$564.94
$28.98 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 30.0%
Every $100 of equity generates 24 in profit
Earnings expanding 31.5% YoY
Keeps 41 of every $100 in revenue as profit
Strong operational efficiency at 41.7%
Safe zone — low bankruptcy risk
Every $100 of equity generates 20 in profit
Areas to Watch
Smaller company, higher risk/reward
Expensive relative to growth rate
Revenue declined 1.6%
Earnings declined 12.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : COLL
The strongest argument for COLL centers on Operating Margin, Return on Equity, EPS Growth. Revenue growth of 12.9% demonstrates continued momentum.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 40.6% and operating margin at 41.7%.
Bear Case : COLL
The primary concerns for COLL are Market Cap.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
COLL profiles as a value stock while UTHR is a declining play — different risk/reward profiles.
COLL carries more volatility with a beta of 0.76 — expect wider price swings.
COLL is growing revenue faster at 12.9% — sustainability is the question.
UTHR generates stronger free cash flow (363M), providing more financial flexibility.
Bottom Line
COLL scores higher overall (65/100 vs 57/100) and 12.9% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Collegium Pharmaceutical Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and markets pain management medications. The company is headquartered in Stoughton, Massachusetts.
United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?